PAVmed, Lucid Diagnostics Pause Some Development Programs, Announce Layoffs
PAVmed, Lucid Diagnostics Pause Some Development Programs, Announce Layoffs
PavMed,Lucid Diagnostics 暂停了一些开发计划,宣布裁员
- PAVmed Inc (NASDAQ:PAVM), its majority-owned subsidiaries Lucid Diagnostics Inc (NASDAQ:LUCD), and Veris Health Inc provided a strategic business update outlining near-term strategic priorities and resource reallocation.
- The companies will prioritize near-term Lucid and Veris Health commercialization efforts.
- They have implemented a workforce reduction of approximately 20%, product portfolio streamlining, and other cost-cutting measures which seek to lower quarterly cash burn by at least 25%.
- Lucid plans to pause further development of the EsoCure Esophageal Ablation device and delay completion of the EsoGuard BE-2 study to the second half of 2023.
- Veris plans to delay the development and regulatory submission of the implantable physiologic monitor to the second half of 2023
- PAVmed will indefinitely pause or halt all other product development activities, including CarpX, PortIO, and NextFlo, and pursue additional cost-cutting initiatives, including not paying annual cash bonuses.
- Price Action: PAVM shares closed 8.10% higher at $0.6326, and LUCD 20% higher at $1.56 on Tuesday.
- PavMed Inc (纳斯达克股票代码:PAVM),其控股子公司 Lucid 诊断公司 (纳斯达克股票代码:LUCD),以及 Veris Health 提供了战略业务最新情况,概述了近期的战略优先事项和资源重新分配。
- 两家公司将优先考虑短期内的Lucid和Veris Health商业化工作。
- 他们已经实施了约20%的裁员,精简了产品组合,并采取了其他削减成本的措施,旨在将季度现金消耗减少至少25%。
- Lucid计划暂停eSocure食管消融设备的进一步开发,并将esoGuard BE-2研究的完成推迟到2023年下半年。
- Veris计划将植入式生理监护仪的开发和监管提交推迟到2023年下半年
- PavMed将无限期暂停或停止所有其他产品开发活动,包括CarpX、PortIO和NextFlo,并采取其他削减成本的举措,包括不支付年度现金奖励。
- 价格走势: 周二,PAVM股价收盘上涨8.10%,至0.6326美元,LUCD股价上涨20%,至1.56美元。